Premium
FMS Kinase Inhibitors: Current Status and Future Prospects
Author(s) -
ElGamal Mohammed I.,
Anbar Hanan S.,
Yoo Kyung Ho,
Oh ChangHyun
Publication year - 2013
Publication title -
medicinal research reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.868
H-Index - 130
eISSN - 1098-1128
pISSN - 0198-6325
DOI - 10.1002/med.21258
Subject(s) - osteolysis , macrophage colony stimulating factor , cancer research , osteoclast , monocyte , inflammation , tyrosine kinase , signal transduction , receptor tyrosine kinase , kinase , macrophage , oncogene , biology , cancer , microbiology and biotechnology , immunology , medicine , receptor , biochemistry , surgery , cell cycle , in vitro
FMS , first discovered as the oncogene responsible for F eline M c D onough S arcoma, is a type III receptor tyrosine kinase that binds to the macrophage or monocyte colony‐stimulating factor ( M ‐ CSF or CSF ‐1). Signal transduction through that binding results in survival, proliferation, and differentiation of monocyte/macrophage lineage. Overexpression of CSF ‐1 and/or FMS has been implicated in a number of disease states such as the growth of metastasis of certain types of cancer, in promoting osteoclast proliferation in bone osteolysis, and many inflammatory disorders. Inhibition of CSF ‐1 and/or FMS may help treat these pathological conditions. This article reviews FMS gene, FMS kinase, CSF ‐1, IL ‐34, and their roles in bone osteolysis, cancer biology, and inflammation. Monoclonal antibodies, FMS crystal structure, and small molecule FMS kinase inhibitors of different chemical scaffolds are also reviewed.